1 High-Flying Stock to Buy Hand Over Fist if the Stock Market Crashes
Key Points Moderna’s personalized cancer vaccine candidate, intismeran autogene, significantly reduced the risk of melanoma recurrence in a Phase 3 trial, a first for a personalized cancer vaccine.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.